Conduit Pharmaceuticals Stock (NASDAQ: CDT)

Dernières nouvelles pour Conduit Pharmaceuticals (NASDAQ:CDT) Stock

Conduit Pharmaceuticals

Conduit Pharmaceuticals Inc is a clinical-stage specialty biopharmaceutical company that was formed to facilitate the development and commercialization of clinical assets that have not been or are not being, prioritized by leading biopharmaceutical companies in order to develop pharmaceutical products that meet the unmet medical needs of patients. The Company's current development pipeline includes a glucokinase activator, which is Phase II ready in autoimmune diseases including uveitis, Hashimoto's Thyroiditis, preterm labor and renal transplant rejection. The Company's development pipeline also includes a potent, irreversible inhibitor of human Myeloperoxidase (MPO) that has the potential to treat idiopathic male infertility.

Conduit Pharmaceuticals Inc. - Common Stock

Conduit Pharmaceuticals Inc

Infinitii Ai Inc

CDT Environmental Technology Investment Holdings Limited - ordinary shares

CDT Environmental Technology Investment Holdings Ltd

CDTI ADVANCED MATERIALS by CDTI Advanced Materials, Inc.

CDTi Advanced Materials Inc

Cidara Therapeutics Inc

Analysts on Monday drew parallels between Bitcoin's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) recent performance and its infamous "Thanksgiving Day Massacre" in 2020, when prices dropped sharply before rebounding <a href="https://www.benzinga.com/money/bitcoin-price-prediction">to new highs</a>.
What Happened: Coinbureau co-founder Nic Puckrin on X <a href="https://x.com/nicrypto/status/1861661962116923470">highlighted</a> that Bitcoin has fallen from just below $100,000 to $91,500 this week, a less severe 8% decline compared to the 17% drop in 2020 from Nov 25 to Nov 27.
In 2020, Bitcoin&#8217;s sharp decline set the stage for a sustained rally. 
For 2024, factors like institutional interest from entities like <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42165734/bitcoin-etfs-registered-record-312-billion-net-inflows-last-week">BlackRock and ETFs</a>, alongside macroeconomic variables such as <a href="https://www.benzinga.com/economics/macro-economic-events/24/11/42198763/fed-minutes-reveal-confidence-in-inflation-reduction-yet-flag-divergent-views-on-interest-rate-path-ahead">inflation and interest rates</a>, play a larger role in shaping the market outlook.
Puckrin noted that on-chain data reveals whales are accumulating Bitcoin, signaling a potential rebound. 
Still, the broader market awaits confirmation of whether retail investors will join or if a deeper correction looms.
Puckrin himself views Thanksgiving dips as moments tied to volatility but often "turning points for new highs." 
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42197276/anthony-scaramucci-trump-win-is-the-greatest-political-comeback-in-us-history-crypto-surge-following-it-was-3-years-overdue">Anthony Scaramucci: Trump Win Is &#8216;The Greatest Political Comeback In US History,&#8217; Crypto Surge Following It Was 3 Years Overdue</a>
Galaxy&#8217;s Head of Research, Alex Thorn, echoed this sentiment, reminding traders of Bitcoin's 2020 Thanksgiving dip, which was followed by a tripling of its price over the next five months.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">who remembers the thanksgiving dump of 2020? bitcoin dumped 17% between wednesday nov 25 and friday nov 27, 2020 btcusd later went on to more than 3x over the next 5 months. does history rhyme? <a href="https://t.co/y2bWV23P9n">pic.twitter.com/y2bWV23P9n</a>
&mdash; Alex Thorn (@intangiblecoins) <a href="https://twitter.com/intangiblecoins/status/1861605206556922055?ref_src=twsrc%5Etfw">November 27, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Recent Santiment data highlighted a dip in social sentiment for major cryptocurrencies like Bitcoin, Ethereum and Solana, which may weigh on <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42163156/why-bitcoins-rally-is-stalling-below-100000">Bitcoin stalling below $100,000.</a>
Standard Chartered&#8217;s analysts anticipate a potential correction, identifying $85,000 to $88,700 as critical support zones before an uptrend resumes.
The bank&#8217;s forecast for Bitcoin includes a <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42192364/bitcoin-correction-could-go-as-deep-as-88700-but-125000-year-end-target-remains-in-play-says-standard-chartered">year-end target of $125,000</a> and $200,000 by the end of 2025. 
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42191142/bitcoin-is-being-sold-into-a-market-with-ample-demand-from-institutions-says-marathon-ceo-fred-thiel">Bitcoin Is Being Sold Into A Market With &#8216;Ample Demand&#8217; From Institutions, Says Marathon CEO Fred Thiel</a></li>
</ul>
Image created using artificial intelligence with Midjourney.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

News

$BTC

Bitcoin's 2020 'Thanksgiving Massacre' To Repeat Or Is The Holiday A 'Turning Point For New Highs'?

B of A Securities analyst Lorraine Hutchinson maintains Urban Outfitters (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/URBN#NASDAQ">URBN</a>) with a Buy and raises the price target from $46 to $53.

Price Target

Analyst Ratings

URBN

B of A Securities Maintains Buy on Urban Outfitters, Raises Price Target to $53

GOEV

Canoo Announced Issuance Of 7,185,125 Shares At $0.3992 Each To Vendors For Services Rendered

Starting April 2025, patients suffering from chronic pain will have greater access to medical marijuana, according to a new decree from the Ministry of Health. Under the expanded access, general practitioners (GPs) in the country will be allowed to prescribe medical marijuana to registered patients with chronic pain, <a href="https://www.expats.cz/czech-news/article/czechia-takes-step-towards-laxer-cannabis-laws-with-new-bill">writes</a> Expats.
Ministry spokesperson Ondřej Jakob <a href="https://www.novinky.cz/clanek/domaci-ministerstvo-ustupuje-poptavce-po-konopi-na-bolest-ho-nove-predepisou-i-praktici-40498698">confirmed </a>to news outlets Novinky and Právo that the new rules are designed to simplify access."The decree allows GPs to prescribe medicinal cannabis for chronic, intractable pain."
Under the current law, only specialized doctors can prescribe cannabis, which is limiting for many patients. According to official data, roughly 8,000 people in the country use cannabis legally, but the demand is much higher. The National Drug Monitoring Center recently revealed results of its survey showing that about 600,000 Czechs use medical marijuana, and more than a million have tried it for self-treatment this year.
"It doesn't make sense that we can prescribe strong opiates like morphine but not medical cannabis," Dr. Petr Šonka, chairman of the Czech Association of General Practitioners, told Novinky. Šonka further stressed the importance of managing pain for terminal patients.
Furthermore, under the new rules, prescriptions will be valid for up to three months, and insurance will still cover 90% of the expense for up to 30 grams of marijuana per month. Coverage for cannabis extracts will also be expanded.
Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/11/41890759/polish-parliamentary-committee-sends-cannabis-decriminalization-petition-to-prime-minister">Polish Parliamentary Committee Sends Cannabis Decriminalization Petition To Prime Minister</a>
Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter <a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you're serious about the business, you can't afford to miss out.
<h2 class="wp-block-heading">Proposal To Allow Cultivation And Possession</h2>
The expanded medical marijuana access follows up on the Czech <a href="https://www.benzinga.com/markets/cannabis/24/11/42043465/czech-government-legalizes-cultivation-of-three-cannabis-plants-allows-possession-of-50-grams">government's proposal</a> of a draft law that would reform&nbsp;criminal law regarding cannabis, with changes including relaxed rules on&nbsp;home cultivation and possession. The draft law now needs to be viewed by both chambers of Parliament.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/10/41295350/czech-senate-approves-restrictions-on-sale-of-kratom-and-hhc-products">Czech Senate Approves Restrictions On Sale Of Kratom And HHC Products</a></li>
</ul>
Photo: Benzinga edit with images by <a href="https://www.pexels.com/@rdne/">RDNE Stock project</a> and <a href="https://www.pexels.com/@jules-clark-624979041/">Jules Clark</a> via Pexels

Cannabis

Czech General Practitioners To Prescribe Medical Marijuana For Chronic Pain With Insurance Coverage Starting 2025

TD Cowen analyst Andrew Kligerman maintains Axis Capital Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AXS#NYSE">AXS</a>) with a Buy and raises the price target from $118 to $127.

TD Cowen Maintains Buy on Axis Capital Holdings, Raises Price Target to $127

<ul>
<li>KODK</li>
<li>NVDA</li>
<li>MSTR</li>
<li>ACHR</li>
<li>DELL</li>
<li>RKLB</li>
<li>TSLA</li>
<li>CORN</li>
<li>AMZN</li>
<li>LOT</li>
</ul>
Data from <a href="https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment" title="https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment">https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment</a>

Trading Ideas

ACHR

AMZN

CORN

DELL

KODK

MSTR

NVDA

RKLB

TSLA

Top 10 Trending Stocks On WallStreetBets As Of November 27, 2024 (Via Swaggy Stocks)

B of A Securities analyst Vivek Arya maintains Ambarella (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMBA#NASDAQ">AMBA</a>) with a Underperform and raises the price target from $57 to $65.

AMBA

B of A Securities Maintains Underperform on Ambarella, Raises Price Target to $65

In the current session, the stock is trading at $22.09, after a 0.41% increase. Over the past month, Ares Capital Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARCC#NASDAQ">ARCC</a>) stock increased by 3.09%, and in the past year, by 11.00%. With performance like this, long-term shareholders are optimistic but others are more likely to look into the price-to-earnings ratio to see if the stock might be overvalued.

<img src="https://www.benzinga.com/files/images/story/2024/1732716911_0.png" alt="Past Year Chart" />

<h3>Ares Capital P/E Ratio Analysis in Relation to Industry Peers</h3>
The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. 
Ares Capital has a lower P/E than the aggregate P/E of 46.03 of the Capital Markets industry. Ideally, one might believe that the stock might perform worse than its peers, but it's also probable that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2024/1732716911_1.png" alt="Guage" />

In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.

Intraday Update

Markets

ARCC

A Look Into Ares Capital Inc's Price Over Earnings

Barclays analyst Pablo Monsivais maintains Corporacion Inmobiliaria (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTMX#NYSE">VTMX</a>) with a Overweight and lowers the price target from $38 to $35.

VTMX

Barclays Maintains Overweight on Corporacion Inmobiliaria, Lowers Price Target to $35

Barclays analyst Adrienne Yih maintains Burlington Stores (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BURL#NYSE">BURL</a>) with a Overweight and lowers the price target from $327 to $317.

BURL

Barclays Maintains Overweight on Burlington Stores, Lowers Price Target to $317

TD Cowen analyst Joshua Buchalter maintains Analog Devices (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADI#NASDAQ">ADI</a>) with a Buy and lowers the price target from $270 to $260.

TD Cowen Maintains Buy on Analog Devices, Lowers Price Target to $260

B of A Securities analyst Ronald Epstein maintains StandardAero (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SARO#NYSE">SARO</a>) with a Neutral and lowers the price target from $34 to $32.

SARO

B of A Securities Maintains Neutral on StandardAero, Lowers Price Target to $32

Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) shares closed slightly <a href="https://www.benzinga.com/quote/AAPL">higher on Tuesday</a>.
Apple is reportedly changing its approach to software updates. The tech giant appears to be opting for staggered rollouts of new features instead of bundling everything into annual iOS releases.
In his latest weekly &#8220;Power On&#8221; newsletter, Bloomberg columnist Mark Gurman said that Cupertino plans a significant update with iOS 18.4 <a href="https://www.benzinga.com/24/11/42183616/apple-could-delay-key-ios-19-features-plans-shifting-to-staggered-rollouts-with-2026-siri-overhaul-and-more">this spring</a>.
With the recent buzz around Apple, some investors may be eyeing potential gains from the company's dividends too. As of now, Apple offers an annual dividend yield of 0.43%, which is a quarterly dividend amount of 25 cents per share ($1.00 a year).
So, how can investors exploit its dividend yield to pocket a regular $500 monthly?
To earn $500 per month or $6,000 annually from dividends alone, you would need an investment of approximately $1,410,360 or around 6,000 shares. For a more modest $100 per month or $1,200 per year, you would need $282,072 or around 1,200 shares.
To calculate: Divide the desired annual income ($6,000 or $1,200) by the dividend ($1.00 in this case). So, $6,000 / $1.00 = 6,000 ($500 per month), and $1,200 / $1.00 = 1,200 shares ($100 per month).
Note that dividend yield can change on a rolling basis, as the dividend payment and the stock price both fluctuate over time.
How that works: The dividend yield is computed by dividing the annual dividend payment by the stock&#8217;s current price.
For example, if a stock pays an annual dividend of $2 and is currently priced at $50, the dividend yield would be 4% ($2/$50). However, if the stock price increases to $60, the dividend yield drops to 3.33% ($2/$60). Conversely, if the stock price falls to $40, the dividend yield rises to 5% ($2/$40).
Similarly, changes in the dividend payment can impact the yield. If a company increases its dividend, the yield will also increase, provided the stock price stays the same. Conversely, if the dividend payment decreases, so will the yield.
AAPL Price Action: Shares of Apple gained 0.9% to close at $235.06 on Tuesday.
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More:
<ul>
<li> <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/42188912/jim-cramer-linde-is-a-terrific-company-sees-another-stock-up-75-as-not-done">Jim Cramer: Linde Is A &#8216;Terrific&#8217; Company, Sees Another Stock Up 75% As &#8216;Not Done&#8217;</a></li>
</ul>
Image via Shutterstock

Long Ideas

AAPL

How To Earn $500 A Month From Apple Stock

Iris Energy Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IREN#NASDAQ">IREN</a>) shares are trading higher Wednesday on the heels of the company&#8217;s first-quarter financial results. Multiple analysts raised price targets following the print. Here&#8217;s what <a href="https://www.benzinga.com/pressreleases/24/11/g42201221/iren-reports-q1-fy25-results">you need to know</a>.
What Happened: After the market close on Tuesday, Iris reported first-quarter Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) mining revenue of $49.6 million. The company reported a 28% increase in AI Cloud Services revenue quarter-over-quarter to $3.2 million. 
Adjusted EBITDA was $2.6 million in the quarter. The company said it mined 813 bitcoin in the period and ended the quarter with $98.6 million in cash and cash equivalents. Iris noted that it had $182.4 million in cash as of Oct. 31.
&#8220;We are pleased to report our Q1 FY25 results and reiterate our focus on low-cost Bitcoin mining, operating cashflows and shareholder returns,&#8221; said Daniel Roberts, co-founder and co-CEO of Iris Energy.
&#8220;We are just weeks away from achieving our 31 EH/s milestone and are excited to announce the acceleration of our growth trajectory to 50 EH/s in H1 2025, which was previously H2 2025.&#8221;
Iris said it had 21 EH/s installed in the quarter and remains on track to achieve 31 EH/s in December. The company currently has an all-in cash cost per bitcoin of approximately $29,000. Bitcoin was hovering around $94,000 at the time of publication, per <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Following the company&#8217;s quarterly results, Canaccord Genuity analyst Joseph Vafi maintained Iris with a Buy and raised the price target from $15 to $17. HC Wainwright &amp; Co. analyst Mike Colonnese maintained a <a href="https://www.benzinga.com/analyst-stock-ratings">Buy rating</a> and raised the price target from $13 to $16, and Needham analyst John Todaro reiterated a Hold rating. 
Check This Out: <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42211674/bitcoin-at-93000-crash-or-pause-bullish-outlook-for-2025-says-10x-research">Bitcoin At $93,000—Crash Or Pause? &#8216;Bullish Outlook For 2025,&#8217; Says 10x Research</a>
IREN Price Action: Iris Energy shares were up 9.52% at $10.47 at the time of publication Wednesday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: Shutterstock.

Movers

IREN

What's Going On With Bitcoin Mining Stock Iris Energy Wednesday?

Barclays analyst Michael Leithead maintains Berry Global Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BERY#NYSE">BERY</a>) with a Equal-Weight and raises the price target from $64 to $75.

BERY

Barclays Maintains Equal-Weight on Berry Global Gr, Raises Price Target to $75

POET Technologies Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POET#NASDAQ">POET</a>) shares are trading lower Wednesday after the company announced a $25 million <a href="https://www.benzinga.com/pressreleases/24/11/g42202419/poet-technologies-announces-us-25-million-registered-direct-offering">registered direct offering</a>.
What Happened: After the market close on Tuesday, POET Technologies announced that it expects to issue 5.55 million common shares and warrants exercisable for 2.78 million common shares.
The company said the combined price of one common share and the accompanying warrant will be $4.50. The warrant will be exercisable at $6 per common share for a period of five years from the date of issuance.
The offering is expected to close on or about Dec. 3. The company expects to raise gross proceeds of $25 million and will use any net proceeds for working capital related to its recently announced plans to <a href="https://www.benzinga.com/24/11/42168802/whats-going-on-with-poet-technologies-stock-monday">expand assembly operations</a> into Malaysia. 
POET Technologies offers high-speed optical engines, light source products and custom optical modules to the <a href="http://benzinga.com/topic/ai">AI</a> systems market and to hyperscale data centers.
See Also: <a href="https://www.benzinga.com/markets/equities/24/11/42211765/dragonfly-energy-sees-over-10-decline-as-new-smart-lithium-batteries-launch-amid-black-friday-event">Dragonfly Energy Sees Over 10% Decline As New Smart Lithium Batteries Launch Amid Black Friday Event</a>
<h3 class="wp-block-heading">How To Buy POET Stock</h3>
By now you're likely curious about how to participate in the market for POET Technologies &#8211; be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy ‘fractional shares,' which allows you to own portions of stock without buying an entire share. 
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to ‘go short' a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.
POET Price Action: POET shares were down 5.14% at $4.79 at the time of writing, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: Shutterstock.

POET

POET Technologies Stock Is Sliding Today: What's Happening?

Barclays analyst Luke Sergott maintains Agilent Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/A#NYSE">A</a>) with a Underweight and lowers the price target from $145 to $135.

Barclays Maintains Underweight on Agilent Technologies, Lowers Price Target to $135

BMO Capital analyst Michael Zaremski maintains Hartford Finl Servs Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIG#NYSE">HIG</a>) with a Market Perform and raises the price target from $100 to $141.

BMO Capital Maintains Market Perform on Hartford Finl Servs Gr, Raises Price Target to $141

Recent listings on Coinbase and Robinhood have invigorated bullish sentiment about Pepe, with traders calling for new all-time highs <a href="https://www.benzinga.com/money/pepe-price-prediction">to come soon.</a>
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Price&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</td>
<td>Market Cap</td>
<td>24-Hour Trend</td>
<td>7-Day Trend</td>
</tr>
<tr>
<td>Pepe (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">PEPE</a>)</td>
<td>$0.00001833 </td>
<td>$7.7 Billion</td>
<td>&nbsp;+1.8%</td>
<td>&nbsp;-9.2%</td>
</tr>
<tr>
<td>Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>)</td>
<td>$0.3934&nbsp;&nbsp;</td>
<td>$57.8 Billion</td>
<td>&nbsp;+4%</td>
<td>&nbsp;+0.99%</td>
</tr>
<tr>
<td>Shiba Inu (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>)</td>
<td>$0.00002499</td>
<td>$14.7 Billion</td>
<td>&nbsp;+4.2%</td>
<td>&nbsp;+1.9%</td>
</tr>
</tbody>
</table>
</figure>
Trader Notes: Crypto trader MaxBecauseBTC sees Pepe standing out in the meme coin space, predicting it will join Dogecoin and Shiba Inu as multi-billion-dollar assets. 
In a <a href="https://x.com/MaxBecauseBTC/status/1861644070910820549">post</a> on X on Tuesday, he emphasized that while most meme coins will fade quickly, Pepe&#8217;s enduring appeal could establish it as a key player in the market.
Max highlights a potential "flight to quality" among investors, moving away from weaker meme coins toward those with stronger speculative value. This shift, he suggests, could lead to a rapid repricing of high-potential assets like Pepe.
Similarly, trader Dami-Defi predicted a "massive breakout" for Pepe in the near future, further cementing its position among top-tier meme coins.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Smart money is accumulating <a href="https://twitter.com/search?q=%24PEPE&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$PEPE</a>! Massive breakout coming soon &#x270d;&#xFE0F; <a href="https://t.co/8UA5qDR6TT">pic.twitter.com/8UA5qDR6TT</a>
&mdash; Dami-Defi (@DamiDefi) <a href="https://twitter.com/DamiDefi/status/1861699007208472723?ref_src=twsrc%5Etfw">November 27, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Statistics: IntoTheBlock data shows large transaction volume increasing by 187.3% and daily active addresses down by 7.2%. Transactions greater than $100,000 remain relatively flat at 446. 
Around 86% of Pepe holders are currently making profit.
Community News: In mid-November, Coinbase <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41945111/pepe-listed-on-robinhood-coinbase-reaches-new-all-time-high-on-44-gain-traders-speculate-about-dogecoin-like-run">listed Pepe on its exchange</a>. 
Robinhood also announced the listing of Pepe on its platform thereby expanding its coverage to a broader U.S. audience.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42097462/dogecoin-millionaire-shares-50-million-meme-coin-strategy-for-2025-pepe-brett-are-this-bull-runs-doge-shiba-inu">&#8216;Dogecoin Millionaire&#8217; Shares $50 Million Meme Coin Strategy For 2025: Pepe, Brett Are This Bull Run&#8217;s DOGE, Shiba Inu</a></li>
</ul>
Image: Shutterstock

$DOGE

$PEPE

$SHIB

Pepe Set to Join Dogecoin, Shiba Inu As Multi-Billion Dollar Meme Coin By 2025: 'Massive Breakout' Coming Soon, Trader Predicts

BMO Capital analyst Keith Bachman maintains CrowdStrike Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>) with a Outperform and raises the price target from $315 to $380.

CRWD

BMO Capital Maintains Outperform on CrowdStrike Holdings, Raises Price Target to $380

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Conduit Pharmaceuticals&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/cdt-stock-quote/">CDT</a>) stock is rocketing higher on Thursday after the clinical-stage specialty biopharmaceutical company announced <a href="https://www.nasdaq.com/press-release/conduit-pharmaceuticals-enters-exclusive-license-agreement-astrazeneca-multiple">an exclusive license agreement</a> with AstraZeneca&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/azn-stock-quote/">AZN</a>).



This has Conduit Pharmaceuticals obtaining exclusive rights for three product candidates in development at AstraZeneca. That includes HK-4 glucokinase activators AZD1656 and AZD5658, as well as myeloperoxidase inhibitor AZD5904.



Development progress includes AZD1656 and AZD5904 already completing Phase 1 clinical trials. Conduit Pharmaceuticals also notes that it intends to launch Phase 2 clinical trials for AZD1656 and AZD5658 this year. It intends to test their effectiveness as autoimmune disorder treatments.



Conduit Pharmaceuticals CEO Dr.&nbsp;David Tapolczay said the following about the deal.




&ldquo;The potential of these assets to become important first-in-class medicines for patients is promising. Given the data from AstraZeneca&rsquo;s clinical trials, we believe there is a strong rationale to initiate Phase II studies in multiple indications to progress to commercialization of these assets.&rdquo;




<h2>CDT Stock Jumps on AZN Agreement</h2>



News of this license agreement brings with it heavy trading of CDT stock. That has more than 39 million shares of AZN trading hands as of this writing. This is well above its daily average trading volume of about 3 million shares.



CDT stock is up 123.2% as of Thursday morning.



Investors will want to stick around for even more of the most recent stock market news today.



We have all of the hottest market happenings worth reading about on Thursday. That includes the biggest pre-market stock movers this morning and more. All of that info is ready to go at the links below!



<h2>More Thursday Stock Market News</h2>



<ul><li><a href="https://investorplace.com/2024/08/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-thursday-aug-8th/">Today&rsquo;s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on&nbsp;Thursday</a></li>



<li><a href="https://investorplace.com/2024/08/ftnt-stock-alert-why-investors-are-piling-into-fortinet-today/">FTNT Stock Alert: Why Investors Are Piling Into Fortinet Today</a></li>



<li><a href="https://investorplace.com/2024/08/why-is-lyft-stock-down-despite-surprise-q2-profits/">Why Is LYFT Stock Down Despite Surprise Q2 Profits?</a></li>
</ul>On Penny Stocks and Low-Volume Stocks:&#8239;With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because these &ldquo;penny stocks&rdquo; are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that&#8239;InvestorPlace.com&rsquo;s writers disclose this fact and warn readers of the risks.



Read More:&#8239;Penny Stocks &mdash;&nbsp;<a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/" target="_blank">How to Profit Without Getting Scammed</a>



On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/2024/08/why-is-conduit-pharmaceuticals-cdt-stock-up-123-today/">Why Is Conduit Pharmaceuticals (CDT) Stock Up 123% Today?</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Why Is Conduit Pharmaceuticals (CDT) Stock Up 123% Today?

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Conduit Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/cdt-stock-quote/">CDT</a>) just reported results for the second quarter of 2024.<ul><li>Conduit Pharmaceuticals reported earnings per share of -7 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/cdt-stock-earnings-conduit-pharmaceuticals-for-q2-of-2024/">CDT Stock Earnings: Conduit Pharmaceuticals Reported Results for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

CDT Stock Earnings: Conduit Pharmaceuticals Reported Results for Q2 2024

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Pre-market stock movers are a hot topic on Wednesday and we have all of the biggest stories traders need to know about this morning!



Moving stocks this morning are earnings reports, a stock offering, a reverse stock split and more.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>Digital Ally (NASDAQ:<a href="https://investorplace.com/stock-quotes/dgly-stock-quote/">DGLY</a>) stock is rocketing more than 107% alongside heavy pre-market trading.</li>



<li>Viracta Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/virx-stock-quote/">VIRX</a>) shares are soaring over 53% with the <a href="https://www.nasdaq.com/press-release/viracta-therapeutics-reports-second-quarter-2024-financial-results-and-provides">release of its Q2 earnings report</a>.</li>



<li>Conduit Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/cdt-stock-quote/">CDT</a>) stock is surging more than 42% on <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318518494&amp;type=PDF&amp;symbol=CDT&amp;cdn=197541151657f71d6ed19abcc1e0e48e&amp;companyName=Conduit+Pharmaceuticals+Inc.&amp;formType=3&amp;formDescription=Initial+statement+of+beneficial+ownership+of+securities&amp;dateFiled=2024-08-13">an investment update</a>.</li>



<li>Nuburu (NYSEMKT:<a href="https://investorplace.com/stock-quotes/buru-stock-quote/">BURU</a>) shares are rising over 26% despite a lack of news this morning.</li>



<li>Jianzhi Education Technology (NASDAQ:<a href="https://investorplace.com/stock-quotes/jz-stock-quote/">JZ</a>) stock is gaining close to 19% even with a <a href="https://www.nasdaq.com/press-release/jianzhi-education-technology-group-company-limited-receives-nasdaq-notification-0">recent delisting notice</a>.</li>



<li>Edible Garden (NASDAQ:<a href="https://investorplace.com/stock-quotes/edbl-stock-quote/">EDBL</a>) shares are increasing more than 18% on <a href="https://www.nasdaq.com/press-release/edible-garden-reports-157-increase-gross-profit-fueled-year-over-year-growth-61-cut">strong Q2 earnings</a>.</li>



<li>Ucloudlink (NASDAQ:<a href="https://investorplace.com/stock-quotes/ucl-stock-quote/">UCL</a>) stock is heading over 16% higher with its <a href="https://www.nasdaq.com/press-release/ucloudlink-group-inc-announces-unaudited-second-quarter-2024-financial-results-2024">most recent earnings report</a>.</li>



<li>Vertex Energy (NASDAQ:<a href="https://investorplace.com/stock-quotes/vtnr-stock-quote/">VTNR</a>) shares are jumping 16% with strong early morning trading.</li>



<li>Serve Robotics (NASDAQ:<a href="https://investorplace.com/stock-quotes/serv-stock-quote/">SERV</a>) stock is climbing more than 15% with its <a href="https://www.stocktitan.net/news/SERV/serve-robotics-announces-second-quarter-2024-wqwtqr037uv4.html">Q2 earnings report</a>.</li>



<li>Kamada (NASDAQ:<a href="https://investorplace.com/stock-quotes/kmda-stock-quote/">KMDA</a>) shares are up over 15% after posting <a href="https://www.nasdaq.com/press-release/kamada-reports-strong-second-quarter-and-first-half-2024-financial-results-year-over">positive Q2 earnings results</a>.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>TC BioPharm (NASDAQ:<a href="https://investorplace.com/stock-quotes/tcbp-stock-quote/">TCBP</a>) stock is crashing more than 42% after <a href="https://www.nasdaq.com/press-release/tc-biopharm-announces-pricing-20-registered-direct-offering-2024-08-13">pricing a registered direct offering</a>.</li>



<li>Surgepays (NASDAQ:<a href="https://investorplace.com/stock-quotes/surg-stock-quote/">SURG</a>) shares are plummeting over 26% after <a href="https://www.prnewswire.com/news-releases/surgepays-announces-second-quarter-2024-financial-results-302221503.html">reporting a Q2 loss</a>.</li>



<li>Arcadia Biosciences (NASDAQ:<a href="https://investorplace.com/stock-quotes/rkda-stock-quote/">RKDA</a>) stock is diving more than 16% after <a href="https://markets.businessinsider.com/news/stocks/rkda-stock-earnings-arcadia-biosciences-for-q2-of-2024-1033684150">missing Q2 EPS estimates</a>.</li>



<li>Ouster (NYSE:<a href="https://investorplace.com/stock-quotes/oust-stock-quote/">OUST</a>) shares are taking an over 16% beating on <a href="https://www.businesswire.com/news/home/20240813944318/en/Ouster-Reports-Strong-Revenue-and-Margins-for-Second-Quarter-2024">mixed Q2 earnings</a>.</li>



<li>QuickLogic (NASDAQ:<a href="https://investorplace.com/stock-quotes/quik-stock-quote/">QUIK</a>) stock is tumbling more than 16% with its <a href="https://www.prnewswire.com/news-releases/quicklogic-reports-41-year-over-year-revenue-growth-for-second-quarter-fiscal-2024-302221555.html">latest earnings release</a>.</li>



<li>Brinker International (NYSE:<a href="https://investorplace.com/stock-quotes/eat-stock-quote/">EAT</a>) shares are sliding over 16% after <a href="https://www.investing.com/news/stock-market-news/brinker-international-stock-tumbles-13-on-q4-earnings-miss-93CH-3570960">posting an earnings miss</a>.</li>



<li>Portage Biotech (NASDAQ:<a href="https://investorplace.com/stock-quotes/prtg-stock-quote/">PRTG</a>) stock is falling more than 15% after <a href="https://www.stocktitan.net/news/PRTG/portage-biotech-announces-1-for-20-reverse-stock-sficaewojjpr.html">announcing a reverse stock split</a>.</li>



<li>Global E Online (NASDAQ:<a href="https://investorplace.com/stock-quotes/glbe-stock-quote/">GLBE</a>) shares are decreasing over 14% with its <a href="https://www.stocktitan.net/news/GLBE/global-e-reports-second-quarter-2024-1dq5hcfetvn1.html">Q2 earnings report</a>.</li>



<li>Bionomics (NASDAQ:<a href="https://investorplace.com/stock-quotes/bnox-stock-quote/">BNOX</a>) stock is dropping more than 14% without any clear news this morning.</li>



<li>WISeKey (NASDAQ:<a href="https://investorplace.com/stock-quotes/wkey-stock-quote/">WKEY</a>) shares close out our pre-market stock movers down nearly 14% on a <a href="https://www.nasdaq.com/press-release/sealcoin-secures-50-million-investment-commitment-gem-digital-limited-through-0">new investment</a> <a href="https://www.nasdaq.com/press-release/wisekey-partners-venafi-post-quantum-encryption-services-2024-08-14">and partnership</a>.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/2024/08/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-wednesday-aug-14th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Conduit Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/cdt-stock-quote/">CDT</a>) stock is up on Wednesday following a shareholder update concerning a major investor in the company.



New filings with the Securities and Exchange Commission (SEC) reveal that Nirland Limited <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318518480&amp;type=PDF&amp;symbol=CDT&amp;cdn=ab0223c3ed6ed1bb801100f67e0b2323&amp;companyName=Conduit+Pharmaceuticals+Inc.&amp;formType=SC+13G%2FA&amp;formDescription=%5BAmend%5D+Statement+of+acquisition+of+beneficial+ownership+by+individuals&amp;dateFiled=2024-08-13">holds a 14.8% stake in CDT stock</a>. This comes from the 12.5 million shares off CDT that the company owns, as well as warrants for another 2 million shares.



Nirland Limited&rsquo;s stake in Conduit Pharmaceuticals is based on the company&rsquo;s outstanding shares of CDT stock. That was sitting at 98,004,699 shares at the time of this writing.



Nirland Limited&rsquo;s stake in Conduit Pharmaceuticals comes from a Senior Secured Promissory Note issued earlier this month. This was part of Conduit Pharmaceuticals&rsquo; merger agreement with Murphy Canyon Acquisition Corp.



<h2>CDT Stock Movement on Wednesday</h2>



Following this news, shares of CDT stock are seeing heavy trading today. This has more than 72 million units changing hands as of this writing. That&rsquo;s a massive increase compared to the company&rsquo;s daily average trading volume of about 10 million shares.



CDT stock is up 11.7% as of Wednesday morning. Even so, the clinical-stage specialty biopharmaceutical company&rsquo;s shares are still down 96.7% since the start of the year.



Investors will want to stick around for even more of the most recent stock market stories on Wednesday!



We have all of the hottest stock market news ready to go today! Among that is what has shares of Intuitive Machines&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/lunr-stock-quote/">LUNR</a>), Nuburu&nbsp;(NYSEMKT:<a href="https://investorplace.com/stock-quotes/buru-stock-quote/">BURU</a>) and Clover Health&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/clov-stock-quote/">CLOV</a>) stock on the move today. You can catch up on all of this at the links below!



<h2>More Stock Market News for Wednesday</h2>



<ul><li><a href="https://investorplace.com/2024/08/trade-of-the-day-explore-the-final-frontier-with-intuitive-machines-lunr-stock/">Trade of the Day: Explore the Final Frontier with Intuitive Machines (LUNR) Stock</a></li>



<li><a href="https://investorplace.com/2024/08/why-is-nuburu-buru-stock-up-47-today/">Why Is Nuburu (BURU) Stock Up 47% Today?</a></li>



<li><a href="https://investorplace.com/2024/08/clov-stock-alert-what-to-know-about-clover-healths-big-insider-buy/">CLOV Stock Alert: What to Know About Clover Health&rsquo;s Big Insider Buy</a></li>
</ul>On Penny Stocks and Low-Volume Stocks:&#8239;With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because these &ldquo;penny stocks&rdquo; are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that&#8239;InvestorPlace.com&rsquo;s writers disclose this fact and warn readers of the risks.



Read More:&#8239;Penny Stocks &mdash;&nbsp;<a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/" target="_blank">How to Profit Without Getting Scammed</a>



On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/2024/08/why-is-conduit-pharmaceuticals-cdt-stock-up-12-today/">Why Is Conduit Pharmaceuticals (CDT) Stock Up 12% Today?</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Why Is Conduit Pharmaceuticals (CDT) Stock Up 12% Today?

06:14 EDT Conduit Pharmaceuticals (CDT) files $100M mixed securities shelf Published first on TheFly – the ultimate source for real-time, market-mo...

Conduit Pharmaceuticals files $100M mixed securities shelf

Conduit Pharmaceuticals ( ($CDT) ) has issued an update. Conduit Pharmaceuticals Inc. recently entered into financial agreements to secure funding,...

Conduit Pharmaceuticals Secures Funding and Modifies Debt Agreements

Conduit Pharmaceuticals announces debt restructuring and additional notes

The latest announcement is out from Conduit Pharmaceuticals ( ($CDT) ). Conduit Pharmaceuticals Inc. has appointed Simon Fry as a director, leverag...

Conduit Pharmaceuticals Announces Leadership Changes and Bylaws Update

Conduit Pharmaceuticals (CDT) announced that the Japan Patent Office, JPO, has granted approval of a composition of matter patent application for t...

Conduit Pharmaceuticals receives further patent approval for AZD1656

The company is not selling any securities under this prospectus and will not receive any proceeds from the sale of its common stock by the selling ...

Comments

Conduit Pharmaceuticals

Actualités

Dernières nouvelles pour Conduit Pharmaceuticals (NASDAQ:CDT) Stock

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL